Pacira BioSciences director's 32,675 options canceled
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pacira BioSciences, Inc. director Thomas G. Wiggans disposed of a directly held stock option covering 32,675 shares on November 17, 2026, the merger’s effective date. The option was canceled and converted into a cash right calculated using the $36.50 per-share offer price less its $23.42 per-share exercise price, subject to applicable tax withholding. Wiggans reported zero options remaining after the transaction.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) F1, F2 | 32,675 | -- | -- |
Footnotes (2)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc. ("Issuer"), Viatris Inc. ("Viatris") and Peach Purchaser Sub Inc. ("Purchaser"), pursuant to which Purchaser consummated a cash tender offer (the "Offer") to purchase all of the outstanding shares of Issuer's common stock (the "Shares") for $36.50 per Share, net of applicable withholding taxes and without interest (the "Offer Price"), after which Purchaser merged with and into Issuer with Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris, on November 17, 2026, the effective time of the Merger (the "Effective Time"), each option to purchase Shares ("Option") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares subject to such Option (continued in Footnote 2)
- F2. immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Option, subject to applicable tax withholdings. Each Option that was outstanding immediately prior to the Effective Time which had a per Share exercise price greater than or equal to the Offer Price was cancelled at the Effective Time with no consideration payable.
Key Figures
Key Terms
cash tender offer financial
Effective Time technical
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many PCRX options did Thomas G. Wiggans dispose of?
AI-generated analysis. How Rhea-AI works. Not financial advice.